An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea
NCT ID: NCT04167462
Last Updated: 2023-03-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
220 participants
INTERVENTIONAL
2019-11-25
2022-01-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
NCT03624127
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03611751
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
NCT05730725
An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis
NCT03924427
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
NCT07251998
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A:BMS-986165 oral administration
BMS-986165
Specified dose on Specified Days
Arm B: Placebo oral administration
Placebo
Specified dose on Specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986165
Specified dose on Specified Days
Placebo
Specified dose on Specified days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate to severe disease
* Candidate for phototherapy or systemic therapy
Exclusion Criteria
* History of recent infection
* Prior exposure to BMS-986165
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0001
Beijing, Beijing Municipality, China
Local Institution - 0007
Beijing, Beijing Municipality, China
Local Institution - 0014
Beijing, Beijing Municipality, China
Local Institution - 0008
Chongqing, Chongqing Municipality, China
Local Institution - 0011
Wuhan, Hubei, China
Local Institution - 0016
Wuhan, Hubei, China
Local Institution
Changsha, Hunan, China
Local Institution
Nanjing, Jiangsu, China
Local Institution - 0002
Changchun, Jilin, China
Local Institution - 0006
Dalian, Liaoning, China
Local Institution - 0018
Taiyuan, Shan1xi, China
Local Institution - 0012
Jingan, Shanghai Municipality, China
Local Institution
Chengdu, Sichuan, China
Local Institution - 0009
Hangzhou, Zhejiang, China
Local Institution - 0003
Hangzhou, Zhejiang, China
Local Institution - 0004
Hangzhou, Zhejiang, China
Local Institution - 0034
Bucheon-si, , South Korea
Local Institution - 0033
Goyang-si, , South Korea
Local Institution - 0028
Gwangju, , South Korea
Local Institution - 0035
Incheon, , South Korea
Local Institution - 0022
Seongnam-si, , South Korea
Local Institution - 0037
Seongnam-si, , South Korea
Local Institution - 0036
Seoul, , South Korea
Local Institution - 0026
Seoul, , South Korea
Local Institution
Seoul, , South Korea
Local Institution - 0021
Seoul, , South Korea
Local Institution - 0020
Seoul, , South Korea
Local Institution - 0027
Seoul, , South Korea
Local Institution - 0024
Seoul, , South Korea
Local Institution - 0023
Suwon, , South Korea
Local Institution - 0029
Kaohsiung City, , Taiwan
Local Institution - 0031
Taipei, , Taiwan
Local Institution - 0032
Taipei, , Taiwan
Local Institution - 0025
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zhang J, Ding Y, Wang P, Li L, Pan W, Lu Y, Cheng H, Jiang X, Ho JC, Guo S, Seo SJ, Gold LS, Blauvelt A, Zhuo J, Zhong Y, Becker B, Liu L, Banerjee S, Thaci D. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial. J Dermatol. 2025 Sep;52(9):1360-1367. doi: 10.1111/1346-8138.17834. Epub 2025 Jul 17.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Investigator Inquiry Form
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM011-065
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.